Discovering Accelerating Transforming
Slingshot is focused on accelerating academic
research towards transformative new drugs.
About us
Slingshot exists to unlock the potential of promising academic drug discovery by progress it at pace.
As a new medicines accelerator, with an initial focus on small molecules, we look across the scientific ecosystem to find high potential breakthroughs.
We provide the platform that enables early-stage science to progress towards drug development in an ever-more complex biotech landscape. Slingshot ensures that innovative scientific discoveries have the opportunity to grow and develop. Our team has the sector expertise, the operational infrastructure and the financial backing, through leading life science investor Syncona, to take ideas all the way to clinical readiness.
Inspired by creativity,
driven by results
We look across the scientific ecosystem to find the most promising early scientific opportunities; identifying pathways that accelerate the journey to a breakthrough medicine.
We are building a pipeline based on several core fundamentals:
World-leading scientists
Assets driven by high-quality founding scientists, at world-leading academic institutions, with a strong track record of research delivery
Targeted disease understanding
Hypothesis-driven science, where disease causality and therapeutic target are tightly linked
Clear development pathways
An attractive path towards the clinic
Significant unmet medical need
Innovative therapies developed to address critical unmet needs and transform patient outcomes
Our Partners
From early-stage vision, to late-stage reality
Our programmes
Fast-tracking the best scientific discoveries
We pinpoint the most promising scientific opportunities, focusing on identifying pathways that accelerate the journey from conceptual, early-stage hypotheses to tangible, breakthrough medicines.
